|
Summary:
Scientists from Evotec AG, together with the Research
Institute of Molecular Pathology in Vienna, will apply
their disease models to identify novel Alzheimer’s
disease targets. Based on these models, Boehringer
Ingelheim will select and further validate target
candidates for its in-house drug discovery program with
the goal of developing novel therapeutics. See full
press release below.
March
19, 2007--Evotec
AG (Frankfurt Stock Exchange: EVT) today announced a
multi-year collaboration with Boehringer Ingelheim to
jointly identify novel targets as potential points of
intervention in the treatment of Alzheimer's disease (AD).
The collaboration will also involve the Research Institute
of Molecular Pathology in Vienna (IMP).
Evotec
scientists together with the IMP will apply their
proprietary and well validated disease models to identify
novel AD targets. Based on these models, Boehringer
Ingelheim will select and further validate target
candidates for its in-house drug discovery programme with
the goal of developing innovative novel therapeutics.
Financial details of this collaboration are not disclosed.
The
contract also includes an option for Evotec to support
Boehringer Ingelheim (BI) in the target validation
process. If BI exercises this option, Evotec is eligible
for milestone payments of up to EUR 20 million plus
royalties.
"Over
the past years, Evotec has built significant expertise in
the field of Alzheimer's and other neurodegenerative
diseases, and our innovative discovery tools and
approaches have successfully been proven together with
renowned industry partners. We are delighted that this
collaboration expands our ongoing successful partnership
with Boehringer Ingelheim into another area of our
strength," said Jorn Aldag, President and Chief
Executive Officer of Evotec.
Contact:
Evotec AG
Anne Hennecke
SVP, Investor Relations &
Corporate Communications
Phone: +49-(0)40-56081-286
Fax: +49-(0)40-56081-333
E-Mail: anne.hennecke@evotec.com
SOURCE
Evotec AG
|
